SS Innovations International Inc

SS Innovations International Inc(SSII)の株式分析

$2.530

-0.049 (-1.94%)終値時点

Loading chart…
高値
2.650
始値
2.580
出来高加重平均価格
2.56
出来高
39.22K
時価総額
—
安値
2.500
売買代金
100.39K
EV/EBITDA(TTM)
-45.51

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset.

ssinnovations.com

AI分析 of SS Innovations International Inc (SSII)

売り

Currently, SS Innovations International Inc (SSII) is not a good buy. The stock is trading at $2.53, which is significantly below its analyst price target of $7, indicating potential upside. However, the stock has shown a year-to-date change of -55.22% and a one-year change of -74.65%, reflecting substantial losses. Additionally, the RSI is at 31.583, suggesting the stock is oversold but also indicating a lack of momentum for recovery. The main risk is the company's negative net income, which was -2,661,350 USD in Q2 2026, highlighting ongoing financial struggles.

バリュエーション指標

SS Innovations International Inc(SSII)の現在の予想PERは0.00で、5年平均は0.00です。

予想PER

大幅な割安
5年平均 P/E
0.00
現在のP/E
0.00
割高
0.00
割安
0.00

予想EV/EBITDA

割安
5年平均 EV/EBITDA
-14.94
現在のEV/EBITDA
-45.51
割高
7.12
割安
-36.99

予想PSR

適正
5年平均 P/S
3.18
現在のP/S
6.79
割高
7.63
割安
-1.27

Alphio AI による SSII の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%SSII

$8.47

シナリオ価格

基

基本

基本 · 50%SSII

$7.13

シナリオ価格

弱

弱気

弱気 · 25%SSII

$6.18

シナリオ価格

イベントタイムライン

2026-10-13 (ET)

09:00:00

SS Innovations Submits Response to FDA Additional Information Request

2026-07-14 (ET)

09:00:00

SS Innovations Appoints Sarah Romano as CFO

2026-05-05 (ET)

09:00:00

SS Innovations Surpasses 10,500 Cumulative Surgeries

2026-05-01 (ET)

16:30:00

SS Innovations Files to Sell 5.02M Shares of Common Stock

16:30:00

SS Innovations Files $150M Mixed Securities Shelf

ニュース

SSII のよくある質問 — Alphio AI が回答

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset. It operates in the Healthcare sector.

Currently, SS Innovations International Inc (SSII) is not a good buy. The stock is trading at $2.53, which is significantly below its analyst price target of $7, indicating potential upside. However, the stock has shown a year-to-date change of -55.22% and a one-year change of -74.65%, reflecting substantial losses. Additionally, the RSI is at 31.583, suggesting the stock is oversold but also indicating a lack of momentum for recovery. The main risk is the company's negative net income, which was -2,661,350 USD in Q2 2026, highlighting ongoing financial struggles.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める